Please login to the form below

Not currently logged in
Email:
Password:

Symkevi

This page shows the latest Symkevi news and features for those working in and with pharma, biotech and healthcare.

Vertex’s triple combination CF therapy to become available on the NHS

Vertex’s triple combination CF therapy to become available on the NHS

Last October, the three parties finally reached an agreement for access to Vertex’s other cystic fibrosis drugs Orkambi (lumacaftor/ivacaftor), Symkevi (tezacaftor/ivacaftor) and Kalydeco (ivacaftor). ... It’s also great news that more mutations have

Latest news

More from news
Approximately 3 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    of CF patients and now Symkevi (ivacaftor and tezacaftor). This is effective for people who have two copies of the F508del mutation plus those with one of 14 other mutations.

  • The Orkambi row explained The Orkambi row explained

    It refuses to file Symkevi with NICE, stating that it will only submit its data if NICE updates its appraisal process. ... December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines

  • The Orkambi blame game The Orkambi blame game

    price of its existing CF treatments Kalydeco and Orkambi, as well as new combination Symkevi and any subsequent products.

  • #OrkambiNow? #OrkambiNow?

    The US company, based in Cambridge, Massachusetts is a pioneer of groundbreaking ‘precision medicine’ drugs against cystic fibrosis Kalydeco (launched in 2012) and Orkambi (2015) and now Symkevi (2018). ... The hope is that both sides can come to a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....